An official website of the United States government
          Here’s how you know
        Here’s how you know**Official websites use .gov**A
              **.gov** website belongs to an official government
              organization in the United States.
        **Secure .gov websites use HTTPS**A
              **lock** (
              Locked padlock icon) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
 Top Utility Nav
        
        
        Asian-Language Resources
        
        Portal en español


Site search Mega Menu
  

        

        Home
                  Health Topics
                                      
    
  Health Topics

    Arthritis and Rheumatic Diseases
          
    Muscle and Bone Diseases
          
    Skin Diseases
          
    All Diseases and Conditions
          
    Publication Catalog
                  Grants & Funding
                                      
    
  Grants & Funding

    Current Funding Opportunities
          
    Supported Scientific Programs
          
    NIAMS-Supported Programs
          
    Applying for a Grant
          
    NIH Policies and Guidance
          
    Peer Review and Grants Administration Resources
          
    Types of Funding Mechanisms (Activity Codes)
                  Labs @ NIAMS
                                      
    
  Labs @ NIAMS

    NIAMS Labs and Core Facilities
          
    Research Faculty
          
    Research Areas
          
    NIAMS Scientific Advances
          
    Training and Career Development
                  Clinical Trials
                                      
    
  Clinical Trials
      
            For Principal Investigators

    Clinical Trial Policies, Guidelines, and Templates
          
    Conducting Clinical Trials
          
    Register with ClinicalTrials.gov

For Patients

What is a Clinical Trial?
	Clinical Trials at NIAMS
	Clinical Trials in the Spotlight
                  News & Events
                                      
    
  Newsroom

    All NIAMS News
          
    NIAMS Newsletters
          
    Meetings & Events
                  About NIAMS
                                      
    
  About NIAMS

    Director's Page
          
    NIAMS Organization
          
    Strategic Plan Fiscal Years 2020-2024
          
    Staff Directory
          
    NIAMS Budget
          
    Partnerships
          
    Contact NIAMS
                  Community Outreach
                                      
    
  Community Outreach

    Bone Health
          
    Joint Health
          
    Muscle, Tendon, and Ligament Health
          
    Skin Health
          
    Health Information For Kids And Young Adults
          
    Health Information For Older Adults/Seniors
          
    Printable Materials for Community Events
          
    Resources in Other Languages
          
    Annual Health Observances
          
    Social Media Resources Breadcrumb
    Home
          Grants & Funding: The NIAMS Extramural Program
          Clinical Trials in the Spotlight
          Treatments Against RA and Effect on FDG-PET/CT (The TARGET Trial)








Treatments Against RA and Effect on FDG-PET/CT (The TARGET Trial) FacebookEmailPrintFacebookEmail     
    The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) supports a range of clinical trials studying new and existing interventions for prevention and treatment of arthritis, musculoskeletal, and skin diseases.  Recruitment for this clinical trial complete.   Updates will be made  to this page when the study completes data analysis and results become available. Please check back often and find out how these studies have contributed to generating new knowledge about diseases and conditions within the NIAMS mission area.

Click on Main Page to learn more about actively recruiting research studies for which you or someone you know may be eligible.

Study Description

Rheumatoid arthritis (RA) is a chronic inflammatory disease, causing joint damage and disability. While remarkable progress in the treatment of RA over the past two decades has improved many outcomes, mortality rates in RA remain 1.5-3-fold above non-RA controls. Cardiovascular disease (CVD) is the leading cause of excess deaths in RA.  Most experts believe that enhanced vascular inflammation underpins accelerated atherosclerosis and CV events yet, there has been no direct proof for this hypothesis. If this is true, then RA therapies that reduce joint inflammation might also reduce CV risk. The lack of an RA-specific CV risk tool hampers evidence-based guidelines, as general population tools perform poorly in RA. These gaps in knowledge create uncertainty for patients and providers in managing RA and its comorbidities. This study proposes to use 18fluoro-deoxyglucose by positron emission tomography/computed tomography (FDG PET/CT) as a novel imaging modality to detect baseline, and disease-modifying antirheumatic drug (DMARD)-associated changes in, vascular inflammation in RA.

The study team will compare the effects on FDG PET/CT of 2 treatment regimens in an RCT among methotrexate (MTX) inadequate responders, representing a critical and common decision point for rheumatologists and patients: addition of a TNFi vs. sulfasalazine + hydroxychloroquine to background MTX. Recent RCTs show near equivalent reduction in articular disease activity, but the relative effects of these regimens on CV risk are unknown. Using data from the RCT, the study team will also compare the effects on vascular inflammation of achieving low disease activity or remission vs. remaining in moderate-high disease activity. These pre-specified secondary analyses will pool the treatment arms to examine whether achievement of a disease activity target associates with greater reduction in vascular inflammation.

**ELIGIBILITY CRITERIA:**

Ages Eligible for Study:           45 Years and older   (Adult, Older Adult)

Sexes Eligible for Study:          All

Accepts Healthy Volunteers:  No

**Inclusion Criteria:**

Fulfill American College of Rheumatology/European League Against Rheumatism 2010 criteria for RA
	Men ≥ 45 years and women ≥ 50 years
	MTX monotherapy for ≥ 8 weeks at ≥ 15mg weekly or ≥ 7.5 mg weekly with a documented intolerance to higher doses
	No non-biologic DMARDs in preceding two months (other than MTX and HCQ)
	Disease Activity Score-28 > 3.2
	Able to sign informed consent**Exclusion Criteria:**

Use of biologic DMARD within the past 6 months or use of rituximab ever
	Current use of >10mg per day of prednisone
	Use of a high-intensity statin lipid lowering drug or PCSK9 inhibitor in the past 12 months
	Prior patient reported, physician diagnosed clinical cardiovascular (CV) event
	Insulin-dependent or uncontrolled diabetes mellitus (DM)
	Systemic lupus erythematosus (SLE) or other autoimmune and chronic inflammatory diseases (i.e. inflammatory bowel disease, sarcoidosis)
	Cancer treated in the last 5 years (except basal and squamous cell) or any lymphoma or melanoma
	Known pregnancy, HIV, Hepatitis B Virus, Hepatitis C Virus, active (or untreated latent) tuberculosis
	Baseline: liver, renal or blood count abnormalities, Glucose-6-phosphate dehydrogenase (G6PD) deficiency
	Known sulfa allergy, macular disease or hypersensitivity to treatments; known demyelinating disease; uncompensated Congestive Heart Failure (CHF)
	Intra-articular injection within the 4 weeks prior to baseline FDG PET/CT
	2 or more high dose radiation scans in the past year (CT scan with contrast, angiogram, SPECT nuclear medicine scan, myocardial/cardiac perfusion scan)**Study Design:**

Allocation: Randomized

Intervention Model:Parallel Assignment

Masking:Single (Outcomes Assessor)

Primary Purpose:Treatment

**Study Location(s):**

University of Alabama at Birmingham, Birmingham, Alabama, United States, 35294

David Geffen School of Medicine at UCLA, Los Angeles, California, United States, 90095

Brigid Freyne, MD Inc. , Murrieta, California, United States, 92563

Desert Medical Advances, Palm Desert, California, United States, 92260

University of California San Francisco , San Francisco, California, United States, 94110

Nazanin Firooz MD, Inc., West Hills, California, United States, 91307

Robert W. Levin, MD, PA, Clearwater, Florida, United States, 33765

Southwest Florida Clinical Research Center, Tampa, Florida, United States, 33609

Northwestern University, Chicago, Illinois, United States, 60611

University of Kentucky, Lexington, Kentucky, United States, 40508

The Center for Rheumatology and Bone Research, Wheaton, Maryland, United States, 20902

Massachusetts General Hospital, Boston, Massachusetts, United States, 02114

Brigham and Women's Hospital, Boston, Massachusetts, United States, 02115

University of Michigan, Ann Arbor, Michigan, United States, 48109

Washington University Medical Center, Saint Louis, Missouri, United States, 63110

Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States, 03756

Jacobi Medical Center, Bronx, New York, United States, 10461

SUNY Downstate Medical Center, Brooklyn, New York, United States, 11203

Northwell Health, Great Neck, New York, United States, 11021

New York University School of Medicine, New York, New York, United States, 10003

Mount Sinai- Icahn School of Medicine, New York, New York, United States, 10029

Columbia University Medical Center, New York, New York, United States, 10032

University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States, 27599

Cleveland Clinic, Cleveland, Ohio, United States, 44195

Oregon Health & Science University, Portland, Oregon, United States, 97329

Altoona Research Center, Duncansville, Pennsylvania, United States, 16635

University of Pennsylvania, Philadelphia, Pennsylvania, United States, 19104

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States, 15261

Baylor Scott and White Research Institute, Dallas, Texas, United States, 75204

Metroplex Clinical Research Center, Dallas, Texas, United States, 75231

University of Texas Health Science Center at Houston, Houston, Texas, United States, 77030

Baylor Scott & White Medical Center- Temple, Temple, Texas, United States, 76508

Seattle Rheumatology Associates, Seattle, Washington, United States, 98122

University of Wisconsin- Madison, Madison, Wisconsin, United States, 53705

**Study Website:**

https://clinicaltrials.gov/ct2/show/NCT02374021?term=NCT02374021&rank=1


Last Updated: February 2021


Back to Top
 About NIAMS
                    Clinical Trials
                    Grants & Funding
                    Health Topics
                    Labs @ NIAMS
              News Room
                    NIAMS Multimedia Library
                    Disclaimer
                    FOIA
                    Contact us
              Privacy Statement
                    Accessibility
                    HHS Vulnerability Disclosure
                    Social Media Moderation Policy
                    NIAMS Archives
        Subscribe to Our E-Newsletters
            Click the button to see different options to sign up for newsletters.
            Click Here to Subscribe
          Follow us on
  
  About NIH
                  Accessibility Support
            FOIA requests
                  No FEAR Act data
            Office of the Inspector General
                  Performance reports
            Privacy Policy